| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the preceding three months, 12 analysts have released ratings for Liquidia (NASDAQ:LQDA), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 4 | 0 | 1 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 5 | 3 | 0 | 1 | 0 |
Analysts have recently evaluated Liquidia and provided 12-month price targets. The average target is $28.83, accompanied by a high estimate of $41.00 and a low estimate of $13.00. This current average has increased by 6.42% from the previous average price target of $27.09.
A clear picture of Liquidia's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ryan Deschner | Raymond James | Raises | Strong Buy | $41.00 | $33.00 |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $31.00 | $25.00 |
| Serge Belanger | Needham | Raises | Buy | $36.00 | $32.00 |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $25.00 | $23.00 |
| Jason Gerberry | B of A Securities | Lowers | Buy | $23.00 | $25.00 |
| Serge Belanger | Needham | Raises | Buy | $32.00 | $25.00 |
| Greg Harrison | Scotiabank | Raises | Sector Outperform | $37.00 | $36.00 |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $23.00 | $20.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $35.00 | $29.00 |
| Serge Belanger | Needham | Maintains | Buy | $25.00 | $25.00 |
| Serge Belanger | Needham | Maintains | Buy | $25.00 | $25.00 |
| Andreas Argyrides | Oppenheimer | Announces | Underperform | $13.00 | - |
To gain a panoramic view of Liquidia's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Liquidia analyst ratings.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Liquidia's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 4.98%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Liquidia's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1229.71%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Liquidia's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -60.43%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Liquidia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.76%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Liquidia's debt-to-equity ratio surpasses industry norms, standing at 2.97. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: LQDA
